Propranolol exhibits activity against hemangiomas independent of beta blockade

M Sasaki, PE North, J Elsey, J Bubley, S Rao… - NPJ precision …, 2019 - nature.com
Propranolol is a widely used beta blocker that consists of a racemic mixture of R and S
stereoisomers. Only the S stereoisomer has significant activity against the beta-adrenergic …

Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression

B Sun, C Dong, H Lei, Y Gong, M Li, Y Zhang… - Chemico-Biological …, 2020 - Elsevier
Hemangioma is one of the commonest benign vascular tumors among children. Propranolol
is the first-line therapeutic drug for hemangioma. However, the effects and mechanisms of …

Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma

H Bessar, AH Kandil, NM Nasr… - Journal of Dermatological …, 2022 - Taylor & Francis
Background The initial recommendation propranolol usage in managing infantile
hemangioma was in 2008 followed by various researches assessing the dosage, efficacy …

Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma

SA Köker, AU Kömüroğlu, AY Köksoy, ÜG Şiraz… - Archives de …, 2021 - Elsevier
Introduction Infantile hemangioma (IH) is a common vascular tumor in children. It is reported
that IHs are associated with immunochemical markers such as vascular endothelial growth …

[HTML][HTML] Dissecting VEGF-induced acute versus chronic vascular hyperpermeability: Essential roles of dimethylarginine dimethylaminohydrolase-1

Y Wang, RS Angom, TA Kulkarni, LH Hoeppner, K Pal… - Iscience, 2021 - cell.com
Vascular endothelial cell growth factor (VEGF) is a key regulator of vascular permeability.
Herein we aim to understand how acute and chronic exposures of VEGF induce different …

[PDF][PDF] ОПТИМІЗАЦІЯ ЛІКУВАЛЬНОЇ ТАКТИКИ ПРИ ГЕМАНГІОМАХ У ДІТЕЙ НА ОСНОВІ ПРОГНОЗУВАННЯ КЛІНІЧНОГО ПЕРЕБІГУ

ВП ВІВЧАРУК - 2022 - knmu.edu.ua
Вивчено особливості морфологічних, клінічних, лабораторних і функціональних
показників у хворих з гемангіомами з урахуванням віку, статі, терміну її появи та початку …